Hormonal
Semaglutide (both oral and subcutaneous formulations) is associated with a high incidence of mild-to-moderate, transient gastrointestinal adverse effects (nausea, vomiting, diarrhea), which are dose-dependent and time-dependent, occurring primarily during the initial 8-12 weeks of treatment.
If you start semaglutide, expect some nausea, vomiting, or diarrhea, especially in the first few months. This is common and usually gets better. To minimize this, start with the lowest dose and follow the doctor's schedule for increasing it slowly. Eat smaller, slower meals and avoid fatty foods. If you take the oral version, take it on an empty stomach with a small sip of water, waiting 30 minutes before eating or drinking anything else.
In the phase 3 trials, both oral and subcutaneous semaglutide were associated with gastrointestinal disturbances, such as nausea, vomiting and diarrhea... Generally, the GI complaints with semaglutide occur in the first 8–12 weeks of treatment during dose escalation... and wane over time... Overall, the adverse effects are mild to moderate in severity and often self-limiting.
Why this rating
Based on extensive phase 3 randomized clinical trials (SUSTAIN and PIONEER programs) involving thousands of participants.
Source
Safety of Semaglutide
Mark M. Smits et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.645563
More from this paper
- Semaglutide does not significantly increase the risk of hypoglycemia in patients not using concomitant insulin or sulfonylureas, due to its glucose-dependent mechanism of action.Strong
- Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.Strong
- Semaglutide increases the risk of biliary disease (cholelithiasis), which is a class effect of GLP-1 receptor agonists, likely due to rapid weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →